Skip to content
CancerIndex

Publication

Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer.

Guoyong Pan, You Li, Jinke Tan, Yuanyuan Chen, Weijiao Chen, Huanaoyu Yang, Xujie Zhuang, Linhu Shen, Ziyu Zong, Yiming Fan, Jiadong Gao, Liping Wang, Xiao-Yu Zhang, Peng Yang, Kai Yuan

Bioorganic chemistryOct 5, 2026PMID 42628378doi:10.1016/j.bioorg.2026.110368 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 11, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260911-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Selective cyclin-dependent kinase (CDK) 4/6 inhibitors play a leading role in the treatment of breast cancer; however, their efficacy is often limited by acquired resistance. Proteolysis-targeting chimera (PROTAC) technology has recently emerged as a promising therapeutic strategy to overcome drug…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.